Orforglipron, a once-daily pill, has outperformed oral semaglutide in a phase 3 clinical trial, showing greater efficacy in managing blood sugar levels and promoting weight loss.
In a phase 3 clinical trial, once-daily orforglipron outperformed semaglutide tablets, the best-known oral version of the GLP ...
Scientists are taking a closer look at the pill forms of Wegovy and Ozempic. In an animal study, the ingredient SNAC, which helps semaglutide survive the stomach and enter the bloodstream, was ...
Drugmaker Lilly said its experimental pill, orforglipron, produced better blood sugar and weight loss for diabetes patients results in a new head-to-head clinical trial.
PHOENIX, AZ - February 27, 2026 - PRESSADVANTAGE - Phoenix NP, a women-focused telehealth medical practice based in ...
An investigational oral glucagon-like peptide-1 (GLP-1) receptor agonist, orforglipron (Eli Lilly), demonstrated superior ...
In today’s Pharma Pulse, Eli Lilly’s orforglipron shows superior blood sugar control over oral semaglutide, while GSK secures ...
A new international study has found encouraging news for people living with both diabetes and heart failure. Researchers ...
Positive results from the aleniglipron Phase 2 ACCESS programs in December 2025 demonstrated significant weight loss across all doses and up to ...
A clinical trial for diabetes that pit orforglipron, a diabetes and weight-loss pill developed by Eli Lilly, against oral ...
An investigational GLP-1 receptor agonist pill edged out oral semaglutide (Rybelsus) for improving blood glucose in adults with type 2 diabetes inadequately controlled on metformin, the phase III ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results